Entresto API is expected to be the largest product in Divi’s Laboratories’ innovator Custom Synthesis (CS) portfolio. Previous Post Glenmark Pharma's Indore unit gets USFDA warning letter; Stock in F&O ban Next Post Anthem Biosciences IPO: GMP at 18% ahead of issue opening on Monday; Should you apply? Leave a ReplyCancel ReplyYour email address will not be published. Required fields are marked * Name * Email * Website Add Comment * Save my name, email, and website in this browser for the next time I comment.Post Comment
